Skip to content
OpenCapital
Get started

Dianthus Therapeutics DNTH Q1 2026 earnings

Reported May 5, 2026 · After market close

Revenue$463.0KBeat by $59.4K
EPS-$0.85Beat by $0.32
Revenue estimate$403.6K
EPS estimate-$1.17

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$297.2K
EPS estimate-$0.93

Financials

Q1 2026

Income statement

See full
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$5.71B+697%
Enterprise value$5.09B+622%

Returns & leverage

See full
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Segments

By product

See full
License$463.0K-60.2%

Versus estimates

Revenue

Q1 2026$463.0KBeat by $59.4K
Q4 2025$284.0KMiss by $268.2KQ3 2025$396.0KMiss by $2.1KQ2 2025$193.0KMiss by $671.7KQ1 2025$1.2MBeat by $356.1KQ4 2024$1.3MBeat by $370.8K

Diluted EPS

Q1 2026-$0.85Beat by $0.32
Q4 2025-$1.43Miss by $0.45Q3 2025-$0.97Miss by $0.11Q2 2025-$0.88Miss by $0.02Q1 2025-$0.82Beat by $0.04Q4 2024-$0.81Beat by $0.04

Ask the moment Dianthus Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Dianthus Therapeutics report Q1 2026 earnings?
Dianthus Therapeutics (DNTH) reported Q1 2026 earnings on May 5, 2026 after market close.
What were Dianthus Therapeutics's Q1 2026 revenue and EPS?
Dianthus Therapeutics reported revenue of $463.0K and eps of $-0.85 for Q1 2026.
Did Dianthus Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $403.6K by $59.4K. EPS beat the consensus estimate of $-1.17 by $0.32.
How did Dianthus Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 60.2% from $1.2M a year earlier and eps declined 3.7% from $-0.82.
Where can I find Dianthus Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001690585-26-000021) and the 10-Q periodic report (0001690585-26-000022) directly on SEC EDGAR. The filing index links above go to sec.gov.